{"id":"W1698939815","doi":"10.1155/2011/724813","title":"Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial","year":2011,"lang":"en","type":"article","venue":"Canadian Journal of Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"ca_institutions":"Abbott (Canada); University of Calgary","funders":"National Institutes of Health; Otsuka America; GlaxoSmithKline; Biogen; ActoGeniX; Bristol-Myers Squibb; Abbott Laboratories","keywords":"Adalimumab; Medicine; Infliximab; Crohn's disease; Internal medicine; Fistula; Surgery; Adverse effect; Disease; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001316704,0.0007904103,0.001090037,0.0001607266,0.001088567,0.0007431896,0.0007080437,0.0007028486,0.002985397],"category_scores_gemma":[0.001322063,0.0002625606,0.0009229673,0.0004851301,0.0006880466,0.0002445003,0.0003015878,0.000964312,0.0002277363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005468393,"about_ca_system_score_gemma":0.008063163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.4214416,"about_ca_topic_score_gemma":0.6343446,"domain_scores_codex":[0.9994942,0.0001445851,0.00002495406,0.00006209042,0.0001452685,0.0001290102],"domain_scores_gemma":[0.9989748,0.0001049832,0.0001788445,0.00003804865,0.0001777317,0.0005256857],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.79146,0.006237627,0.09646464,0.002090672,0.003346331,0.0002476967,0.0004736692,0.0006476578,0.005712383,0.0004571648,0.01040242,0.08245977],"study_design_scores_gemma":[0.3090716,0.04778197,0.6194128,0.0003426836,0.003897444,0.0004373399,0.0003981349,0.001475891,0.001216321,0.0002546393,0.01559294,0.0001182094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985118,0.007758738,0.00009617627,0.0006251064,0.00009414971,0.0004609609,0.002587735,0.00001842927,0.00324069],"genre_scores_gemma":[0.9930711,0.002430368,0.0003926694,0.0004120131,0.0001378063,0.0001723196,0.001996629,0.00000459914,0.001382431],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4214416,"threshold_uncertainty_score":0.8379772,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008497716515170643,"score_gpt":0.2081001138199709,"score_spread":0.1996023973048003,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}